SoniVie Ltd., a company that focuses on developing a unique renal denervation system to address hypertension, has recently appointed Raymond W. Cohen as the chairman of its board of directors. This decision comes as a strategic move to leverage Cohen’s extensive experience in the medical technology sector, particularly in growing companies like Axonics, Inc. and Vessix Vascular, Inc.
Raymond W. Cohen is a seasoned public company director with a remarkable track record of over 40 years in the life sciences industry. He co-founded Axonics, Inc., a global medical technology company that went public in 2018 and was later acquired by Boston Scientific Corporation for $3.7 billion. Cohen’s leadership at Axonics earned the company top rankings in the Deloitte Technology Fast 500™ and Financial Times list of fastest-growing companies in the Americas.
In addition to his role at SoniVie, Cohen also serves as an independent director of Kestra Medical Technologies, Inc., a company specializing in wearable defibrillator products for patients at temporary risk of cardiac arrest. His exceptional contributions to the medical technology field have been recognized through prestigious awards such as the MedTech MVP Award and Businessperson of the Year by the Orange County Business Journal.
SoniVie’s innovative TIVUS™ (Therapeutic Intra-Vascular Ultrasound System) is designed to use high-frequency non-focused ultrasound energy to target nerves in the renal artery, thereby reducing blood pressure in patients with hypertension. This condition affects millions of individuals globally and significantly increases the risk of cardiovascular diseases. The company’s PMA study has received approval from the FDA and is currently enrolling patients in the US, Europe, and Israel.
The “THRIVE” study, conducted by SoniVie, is an international research initiative aimed at demonstrating the safety and effectiveness of the TIVUS™ System in hypertensive individuals. This multicenter study involves a randomized, double-blind, sham-controlled design to assess the impact of the technology on patients who have discontinued anti-hypertensive medications. The results of the study are expected to provide valuable insights into the potential benefits of SoniVie’s innovative approach to managing hypertension.
With operations in Israel, the US, and Europe, SoniVie is well-positioned to make a significant impact in the field of medical technology. The company’s commitment to advancing renal denervation technology underscores its dedication to improving the lives of patients with hypertension and reducing the burden of cardiovascular diseases worldwide.
For more information about SoniVie and its groundbreaking TIVUS™ System, visit www.sonivie.com. For media inquiries, please contact Tomaso Zambelli, CEO of SoniVie Ltd., at [email protected]
